Exabis Library
Welcome to the e-CCO Library!
P646: Refinement of surgical technique offsets increased severity of Crohn’s disease and co-morbidities to maintain low post-operative morbidity
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P646: Relative association of bowel urgency clinically meaningful improvement and bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Work Productivity and Activity Impairment Scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 Phase 3 clinical trials.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P646: The Loss of Productivity in Employment and Education Associated to Inflammatory Bowel Diseases: A Pilot Study of the Patient’s Perception
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P646: Will the screening of SARS-COV-2 infection in IBD infusion centers be useful?
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P647 Post-marketing evaluation of reported adverse events of a multi-strain probiotic product confirms that change in manufacturing site had no impact on safety profile
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P647: A pilot study: The importance of cognitive flexibility and flexibility in coping with stress for the quality of life in inflammatory bowel disease patients during biological therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P647: Awareness, knowledge and use of mesenchymal stem cells – a global survey among gastroenterologists and colorectal surgeons
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P647: Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P647: Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P648: Anti-TNF-α therapy, use of corticosteroids, and colectomy among paediatric and adolescent patients with ulcerative colitis: a nationwide study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P648: Clinical feasibility of dried blood sampling for infliximab in IBD patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P648: Effectiveness of Biologic Therapies in Decreasing Risk of Hospitalization and Surgery, Maintaining Steroid Free Remission and Achieving Mucosal Healing in Inflammatory Bowel Disease; Real World Data.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P648: Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P648: Prevalence and Impact of Alcohol Consumption and Cannabis Use on Inflammatory Bowel Diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P649 Dietary habits in patients with inactive Crohn’s disease: Results of a controlled study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM